Opendata, web and dolomites

ENDFLU SIGNED

Evaluation of ratioNally Designed Influenza vaccines

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 ENDFLU project word cloud

Explore the words cloud of the ENDFLU project. It provides you a very rough idea of what is the project "ENDFLU" about.

conserved    plan    nanoparticles    complementary    demonstration    na    artificial    ing    m2e    protective    expertise    clinically    mediated    ferrets    optimized    mva    cell    constructs    efficacy    vaccination    protein    enter    broadly    safety    manufacturing    clade    internal    scientific    advocacy    model    create    candidates    proteins    manifestations    combined    achievements    criteria    india    assessing    stem    strategies    expressed    rationally    combat    functional    cross    gmp    repository    h5    mice    encode    indian    compliant    followed    optimal    biochemical    rational    encoding    immunogenicity    influenza    toward    dose    optimize    combination    infection    endflu    humoral    epitopes    polyepitope    construct    formulation    immunity    head    worldwide    either    surface    clinical    adoption    fueled    fusions    elicit    select    pandemic    world    hemagglutinin    biophysical    vaccine    designed    seeds    chim    human    trial    generation    induces   

Project "ENDFLU" data sheet

The following table provides information about the project.

Coordinator
STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER 

Organization address
address: BUNTEWEG 2
city: HANNOVER
postcode: 30559
website: www.tiho-hannover.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 14˙444˙867 €
 EC max contribution 8˙646˙254 € (60%)
 Programme 1. H2020-EU.3.1.2. (Preventing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-04-01   to  2025-03-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER DE (HANNOVER) coordinator 1˙234˙225.00
2    CURVE CLINICAL BV NL (AMSTERDAM DUIVENDRECHT) participant 3˙364˙571.00
3    LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN DE (MUENCHEN) participant 2˙342˙075.00
4    VIB BE (ZWIJNAARDE - GENT) participant 608˙750.00
5    UNIVERSITEIT UTRECHT NL (UTRECHT) participant 435˙707.00
6    LUNDS UNIVERSITET SE (LUND) participant 360˙925.00
7    ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE CH (LAUSANNE) participant 300˙000.00
8    COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH IN (NEW DEHLI) participant 0.00
9    INDIAN INSTITUTE OF SCIENCE IN (BANGALORE) participant 0.00
10    INDIAN INSTITUTE OF SCIENCE EDUCATION AND RESEARCH THIRUVANANTHAPURAM IN (THIRUVANANTHAPURAM) participant 0.00
11    MANIPAL ACADEMY OF HIGHER EDUCATION IN (MANIPAL) participant 0.00
12    MYNVAX PRIVATE LIMITED IN (BANGLADORE) participant 0.00
13    SETH G S M COLLEGE AND K E M HOSPITAL DIAMOND JUBILEE SOCIETY IN (MUMBAI) participant 0.00
14    TRANSLATIONAL HEALTH SCIENCE AND TECHNOLOGY INSTITUTE IN (FARIDABAD) participant 0.00

Map

 Project objective

ENDFLU will develop three complementary next-generation influenza vaccination strategies for the world, fueled by the unique combined expertise of Indian and European partners in rational vaccine design and development: • Create a repository of pre-pandemic GMP-compliant MVA-based vaccine seeds, each encoding an influenza hemagglutinin (HA), based on European partners demonstration of clinical safety and cross-clade immunogenicity of MVA-H5. • Optimize and select protein- and MVA-based constructs developed by Indian and European ENDFLU partners, resulting in a rationally combined vaccine formulation that induces broadly protective humoral and cell-mediated immunity against all influenza manifestations. This will be advanced in a Phase I clinical trial and Controlled Human Infection Model (CHIM) study. • Pre-clinically advance other promising protein- and MVA-based constructs toward future development beyond ENDFLU. Constructs to elicit humoral immunity build on rationally-designed and optimized conserved epitopes of influenza surface proteins, HA stem- and HA head-nanoparticles, and NA-M2e fusions either as proteins or MVA expressed. Other MVA-based constructs to elicit cell-mediated immunity will encode conserved internal protein T cell epitopes, as an artificial polyepitope. The best candidates will be selected based on biochemical, biophysical, functional and manufacturing criteria, and immunogenicity and protective efficacy in mice and ferrets. The selected protein-based construct will enter a Part A Phase I clinical trial in India assessing safety, immunogenicity and optimal dose, to be combined with the selected MVA-based construct. This protein-MVA combination will enter a Part B Phase I clinical trial in the EU, assessing safety and immunogenicity, followed by the CHIM study. A dissemination and exploitation plan, and collaboration with key scientific advocacy organizations will facilitate the adoption of ENDFLU achievements to combat influenza worldwide.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ENDFLU" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ENDFLU" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.2.)

EMPOWER (2020)

European platforM to PromOte Wellbeing and HEalth in the woRkplace

Read More  

RISCC (2020)

RISK-BASED SCREENING FOR CERVICAL CANCER

Read More  

HEAP (2020)

Human Exposome Assessment Platform

Read More